eMed
The company will use the funds to expand its agentic AI platform and fund new models for employers, including access to GLP-1 medications.
The deal comes less than a month after the company's plan to combine with digital neurotherapy company MindMaze fell through.
Patients are virtually guided through the steps of sample collection and testing.